How effective is OPZELURA cream for vitiligo treatment?

The efficacy of OPZELURA was confirmed in two large-scale phase 3 clinical trials involving 674 patients aged 12 years and older with nonsegmental vitiligo.

Patients used OPZELURA cream or a placebo twice daily for 24 weeks, after which all patients used OPZELURA to continue treatment for a total of 52 weeks.

Here, F-VASI75 means a 75% or greater improvement in facial vitiligo score compared to before treatment.

The fact that treatment response was higher at 52 weeks than at 24 weeks shows that consistent treatment and time are important in vitiligo therapy.

In a study that re-analyzed the results of the 674-patient clinical trial according to patient characteristics, relatively similar treatment efficacy was observed across diverse patient groups regardless of age, sex, skin color, duration of vitiligo, or prior treatment experience.

In other words, it can be seen as a treatment that shows the potential for repigmentation in a variety of patients with nonsegmental vitiligo, rather than being effective only in specific age groups or skin types.

However, since not all patients have the same treatment response, the location and extent of vitiligo and the condition of the lesions should be considered together in actual treatment.

Not necessarily.

This phase 3 clinical trial was conducted only in patients with nonsegmental vitiligo. Therefore, it is not yet clear whether the same effect occurs in segmental vitiligo.

In addition, the patients in the study had vitiligo involving less than 10% of the total body surface area. Whether the same effect occurs in patients with more extensive vitiligo requires further research and real-world experience.

Patients with white hair in the facial vitiligo area were also excluded from the study. Lesions with white hair often respond poorly to conventional phototherapy or medication, so surgical treatment may be considered.

Therefore, it is difficult to say that OPZELURA replaces all existing vitiligo treatments such as phototherapy or surgical treatment.

In clinical trials, most patients continued treatment without significant issues.

The most common adverse reactions were acne or itching at the application site, occurring in about 5–6% of patients. Most were mild in severity.

Thus, OPZELURA has gained attention as a new option for vitiligo treatment, demonstrating not only efficacy but also a relatively favorable safety profile.

OPZELURA offers another treatment possibility for vitiligo patients who have not achieved satisfactory results with existing treatments or have been waiting for new treatment methods.

It is particularly significant in that a JAK inhibitor that regulates the immune signals involved in vitiligo has demonstrated actual repigmentation effects.

Even after the introduction of OPZELURA, various new vitiligo treatments, including JAK inhibitors, are being studied.

Although not all vitiligo can yet be resolved with a single treatment, it is a clear change that the treatment options available are gradually diversifying according to the patient's vitiligo type and extent.